[go: up one dir, main page]

ECSP21070640A - Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento - Google Patents

Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento

Info

Publication number
ECSP21070640A
ECSP21070640A ECSENADI202170640A ECDI202170640A ECSP21070640A EC SP21070640 A ECSP21070640 A EC SP21070640A EC SENADI202170640 A ECSENADI202170640 A EC SENADI202170640A EC DI202170640 A ECDI202170640 A EC DI202170640A EC SP21070640 A ECSP21070640 A EC SP21070640A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical composition
variant
human
present disclosure
amino acid
Prior art date
Application number
ECSENADI202170640A
Other languages
English (en)
Inventor
Jae Park Soon
Chung Hye-Shin
KIM Kyuwan
Byun Minsoo
Seok NAM Ki
Joo Lee Seung
Original Assignee
Alteogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72611090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21070640(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alteogen Inc filed Critical Alteogen Inc
Publication of ECSP21070640A publication Critical patent/ECSP21070640A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación se refiere a una composición farmacéutica que incluye (a) un medicamento y (b) una variante de PH20 humana. La variante de la PH20 humana incluida en la composición farmacéutica según la presente divulgación incluye sustitución(es) de residuos de aminoácidos en una o más regiones seleccionadas de una región de la hélice alfa 8 (S347 a C381) y una región de enlace (A333 a R346) entre la hélice alfa 7 y la hélice alfa 8 en la PH20 humana de tipo salvaje que tiene la secuencia de aminoácidos de SEC ID NO: 1, en la que el(los) residuo(s) de aminoácidos situado(s) en la N-terminal o la C-terminal se escinde(n) selectivamente. Además, la composición farmacéutica según la presente divulgación puede incluir además un aditivo farmacéuticamente aceptable, en particular un estabilizador. La composición farmacéutica según la presente divulgación puede maximizar el efecto terapéutico de un medicamento utilizado en combinación con la misma, debido al efecto de las variantes humanas de PH20.
ECSENADI202170640A 2019-03-25 2021-09-22 Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento ECSP21070640A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20190033880 2019-03-25

Publications (1)

Publication Number Publication Date
ECSP21070640A true ECSP21070640A (es) 2021-11-18

Family

ID=72611090

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202170640A ECSP21070640A (es) 2019-03-25 2021-09-22 Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento

Country Status (25)

Country Link
US (2) US20210363270A1 (es)
EP (2) EP3785701A4 (es)
JP (4) JP7295150B2 (es)
KR (3) KR20230037691A (es)
CN (7) CN120053665A (es)
AU (2) AU2020248612B9 (es)
BR (1) BR112021019076A2 (es)
CA (1) CA3131052A1 (es)
CL (1) CL2021002464A1 (es)
CO (1) CO2021012380A2 (es)
CR (1) CR20210489A (es)
DO (1) DOP2021000197A (es)
EA (1) EA202192588A1 (es)
EC (1) ECSP21070640A (es)
IL (1) IL286539A (es)
JO (1) JOP20210262A1 (es)
MX (2) MX2021011278A (es)
MY (1) MY204342A (es)
NI (1) NI202100085A (es)
PE (1) PE20220283A1 (es)
PH (1) PH12021552351A1 (es)
SA (1) SA521430398B1 (es)
SG (1) SG11202110512WA (es)
WO (1) WO2020197230A1 (es)
ZA (2) ZA202108027B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
CA2861919C (en) 2011-12-30 2019-04-02 Halozyme, Inc. Ph20 polypeptide variants, formulations and uses thereof
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CN118948760A (zh) 2018-05-10 2024-11-15 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
JP7204729B2 (ja) 2018-07-25 2023-01-16 アルテオゼン インコーポレイテッド 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
AU2021211348B2 (en) * 2020-01-23 2023-10-05 Alteogen, Inc Novel hyaluronic acid-hydrolyzing enzyme variant having improved stability and pharmaceutical composition comprising same
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
MX2023000760A (es) 2020-07-17 2023-02-13 Geron Corp Composiciones subcutaneas del inhibidor de la telomerasa y metodos para su uso.
CN115427562B (zh) 2020-08-07 2025-05-09 阿特根公司 制备重组玻尿酸酶的方法
AR123585A1 (es) * 2020-09-24 2022-12-21 Merck Sharp & Dohme Formulaciones estables de anticuerpos programados del receptor de muerte 1 (pd-1) y variantes de hialuronidasa y fragmentos de las mismas y métodos de uso de las mismas
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
HRP20250628T1 (hr) * 2020-12-28 2025-07-18 Bristol-Myers Squibb Company Mješavine antitijela i postupci njihove upotrebe
MX2023007650A (es) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Metodos de tratamiento de tumores.
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
US20240156907A1 (en) * 2021-03-16 2024-05-16 Kashiv Biosciences, Llc Novel formulation of fusion protein
TW202305009A (zh) * 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
CN115671267A (zh) * 2021-07-23 2023-02-03 上海宝济药业有限公司 一种皮下抗生素药物组合物
MX2024001631A (es) 2021-08-02 2024-04-19 argenx BV Formas de dosificación unitaria subcutánea.
US20240392273A1 (en) 2021-09-14 2024-11-28 Takeda Pharmaceutical Company Limited Facilitated delivery of concentrated antibody formulations using hyaluronidase
KR20230064559A (ko) * 2021-10-29 2023-05-10 (주)알테오젠 인간 히알루로니다제 ph20과 약물을 포함하는 약학 조성물
WO2023168305A1 (en) 2022-03-01 2023-09-07 Exuma Biotech Corp. Viral particles with membrane-bound hyaluronidase
IL314840A (en) * 2022-03-07 2024-10-01 Mabxience Res S L Stable Antibody Formulations
KR20230150203A (ko) * 2022-04-20 2023-10-30 주식회사 알토스바이오로직스 오크렐리주맙(Ocrelizumab)을 포함하는 약학적 조성물과 그의 용도
EP4531916A1 (en) 2022-06-02 2025-04-09 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4545637A1 (en) * 2022-06-22 2025-04-30 Alteogen, Inc. N-terminal and/or c-terminal cleaved soluble ph20 polypeptide and use thereof
WO2024005502A1 (ko) * 2022-06-29 2024-01-04 주식회사 오디스젠 중성 ph에서 활성을 나타내는 히알루로니다제 hyal1 변이체
KR20240038901A (ko) * 2022-09-16 2024-03-26 (주)피앤피바이오팜 신규한 히알루로니다제 ph-20 변이체 및 그 용도
WO2024117476A1 (ko) * 2022-11-28 2024-06-06 주식회사 대웅제약 생체이용률이 개선된 니클로사마이드 함유 조성물
PE20252239A1 (es) 2022-12-22 2025-09-15 Halozyme Inc Formulaciones de enzimas hialuronidasa para administracion de alto volumen
KR102554775B1 (ko) * 2023-02-07 2023-07-12 한국코러스 주식회사 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형
KR20250162568A (ko) * 2023-03-23 2025-11-18 (주)알테오젠 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
WO2024263643A1 (en) * 2023-06-19 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating breast cancer
TW202517294A (zh) * 2023-07-11 2025-05-01 美商建南德克公司 用於治療多發性硬化症之組成物及方法
WO2025071366A1 (ko) * 2023-09-27 2025-04-03 삼성바이오에피스 주식회사 항-il-23 항체의 자가-완충 액상 제형
KR20250086876A (ko) * 2023-12-06 2025-06-16 (주)한국비엠아이 히알루로니다제 폴리펩티드와 약물을 포함하는 피하투여용 조성물
WO2025136032A1 (ko) * 2023-12-21 2025-06-26 주식회사 오디스젠 개선된 특성을 갖는 히알루로니다제 hyal2 변이체
KR102896967B1 (ko) * 2023-12-21 2025-12-09 주식회사 오디스젠 개선된 특성을 갖는 히알루로니다제 Hyal2 변이체
WO2025168089A1 (zh) * 2024-02-08 2025-08-14 上海宝济药业股份有限公司 用于皮下给药的药物组合及其应用
WO2025188901A1 (en) * 2024-03-05 2025-09-12 Halozyme, Inc. Combination therapy with antibody-drug conjugates and hyaluronidases
US20250332255A1 (en) * 2024-04-30 2025-10-30 Context Therapeutics Inc. Compositions comprising bispecific antibodies that bind to claudin 6 and cd3, and uses thereof
WO2025249934A1 (ko) * 2024-05-29 2025-12-04 (주)알테오젠 성장 호르몬 수용체 길항제 및 지속성 담체를 포함하는 피하 주사용 약학 조성물
WO2025264972A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-4r alpha and antibodies that bind
WO2025264960A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-13 and antibodies that bind ox40l

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG177008A1 (en) * 2003-03-05 2012-01-30 Halozyme Inc Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
JP2009515521A (ja) * 2005-11-10 2009-04-16 レセプター バイオロジックス， インコーポレイテッド レセプターアイソフォームおよびリガンドアイソフォームの産生のための方法
TWI489994B (zh) * 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
EP2285402A2 (en) * 2008-04-14 2011-02-23 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
US8927249B2 (en) * 2008-12-09 2015-01-06 Halozyme, Inc. Extended soluble PH20 polypeptides and uses thereof
US20100305500A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
AU2013202020B2 (en) * 2009-07-31 2014-11-27 F. Hoffmann-La Roche Ag Subcutaneous anti-HER2 antibody formulation
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
CA2861919C (en) * 2011-12-30 2019-04-02 Halozyme, Inc. Ph20 polypeptide variants, formulations and uses thereof
TW201534726A (zh) * 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
JP6537076B2 (ja) * 2014-07-31 2019-07-03 国立大学法人神戸大学 分泌シグナルペプチドならびにそれを利用したタンパク質の分泌および細胞表層提示
WO2016033555A1 (en) * 2014-08-28 2016-03-03 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
KR101843927B1 (ko) * 2015-10-27 2018-03-30 주식회사 이에이치엘바이오 15-pgdh 억제제를 처리한 세포 또는 그것의 배양물을 포함하는 조성물과 그의 용도
BR112019010947A2 (pt) * 2016-11-30 2019-10-01 Memorial Sloan Kettering Cancer Center nanopartículas ultrapequenas funcionalizadas por inibidores e métodos das mesmas
KR20190096384A (ko) * 2017-03-02 2019-08-19 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7204729B2 (ja) * 2018-07-25 2023-01-16 アルテオゼン インコーポレイテッド 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物

Also Published As

Publication number Publication date
CN120053665A (zh) 2025-05-30
AU2024201238A1 (en) 2024-03-14
JP7166478B2 (ja) 2022-11-07
EP4461811A3 (en) 2025-01-08
AU2020248612B9 (en) 2023-11-30
JOP20210262A1 (ar) 2023-01-30
JP2025102750A (ja) 2025-07-08
US20220289864A1 (en) 2022-09-15
AU2020248612A1 (en) 2021-10-21
EP3785701A1 (en) 2021-03-03
WO2020197230A1 (ko) 2020-10-01
CN112203642B (zh) 2025-03-07
JP2021526542A (ja) 2021-10-07
JP2023078146A (ja) 2023-06-06
PH12021552351A1 (en) 2022-09-12
ZA202108027B (en) 2022-12-21
IL286539A (en) 2021-10-31
CN117100867A (zh) 2023-11-24
MX2024009997A (es) 2024-12-06
US20210363270A1 (en) 2021-11-25
NI202100085A (es) 2021-12-06
EA202192588A1 (ru) 2022-03-17
CN116870164A (zh) 2023-10-13
CN120053666A (zh) 2025-05-30
DOP2021000197A (es) 2021-11-15
KR20220075238A (ko) 2022-06-07
EP4461811A2 (en) 2024-11-13
AU2020248612B2 (en) 2023-11-23
AU2024201238B2 (en) 2026-02-12
CA3131052A1 (en) 2020-10-01
CN112203642A (zh) 2021-01-08
BR112021019076A2 (pt) 2021-11-30
CR20210489A (es) 2021-12-07
KR20230037691A (ko) 2023-03-16
JP2022095925A (ja) 2022-06-28
CL2021002464A1 (es) 2022-07-22
CN121015892A (zh) 2025-11-28
SG11202110512WA (en) 2021-10-28
MY204342A (en) 2024-08-24
ZA202209369B (en) 2023-07-26
CO2021012380A2 (es) 2021-10-20
JP7295150B2 (ja) 2023-06-20
CN116870164B (zh) 2024-07-23
KR20200130451A (ko) 2020-11-18
PE20220283A1 (es) 2022-02-25
CN120053667A (zh) 2025-05-30
MX2021011278A (es) 2022-03-17
KR102507853B1 (ko) 2023-03-10
KR102650991B1 (ko) 2024-03-27
SA521430398B1 (ar) 2024-05-14
EP3785701A4 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
NI202100085A (es) Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento
MX2024005173A (es) Composicion farmaceutica que comprende hialuronidasa humana ph20 y farmaco.
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
AU2019311658A8 (en) Novel hyaluronidase variants and pharmaceutical composition comprising the same
ES2986021T3 (es) Proteína factor 1 para la utilización en el tratamiento o prevención de enfermedades
AR105616A1 (es) Proteínas de fusión
BR112021022739A2 (pt) Variante de ph20 ou fragmento, método de produção e composição para tratar câncer compreendendo a variante ou fragmento da mesma
PE20090932A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1
PE20191203A1 (es) Variantes de alfa-glucosidasa acida y usos de las mismas
NO345236B1 (no) Glukagonlignende peptid-2 (GLP-2) analoger, farmasøytiske sammensetninger inneholdende slike og anvendelse for fremstillingen av et medikament for behandlingen og/eller forebyggingen av en mage- og tarmrelatert lidelse, samt nukleinsyremolekyl, ekspresjonsvektor, vertscelle og fremgangsmåter for fremstilling av GLP-2 analogene og et terapeutisk sett.
AR064555A1 (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
CO6260151A2 (es) Peptido de cdh3 y agente medicinal que comprende al mismo
CO2020013221A2 (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
AR123187A1 (es) Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer
AU2025220790A1 (en) Pharmaceutical composition for preventing or treating periodontal disease or luxated teeth
PE20220500A1 (es) POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15
US20180170983A1 (en) New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive Impairment
AR061825A1 (es) Analogos del peptido intestinal vasoactivo (vip)
AR119231A1 (es) Agonistas de il2
BR0318594A (pt) proteìna recombinante que possui um efeito anticancerìgeno, seu gene de codificação e usos desta
PE20211772A1 (es) Inmunoterapia con peptidos restringidos a b 08 y una combinacion de peptidos contra el cancer y metodos relacionados
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
MX2022008748A (es) Administración oral de péptidos.